CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 116 enrolled / 116 target
Drug / intervention
MGL-3196 (resmetirom) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03038022
NCT03038022Phase 2CompletedMonitor (1.0/mo)Completion was 101mo ago
CompareCT.gov

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia

Madrigal Pharmaceuticals, Inc.·interventional·Posted Jan 31, 2017·Updated Jun 4, 2026

In Brief

A Phase 2 clinical trial evaluating MGL-3196 (resmetirom) and Placebo for Heterozygous Familial Hypercholesterolemia. Completed, enrolled 116 participants across 13 sites in 3 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in participants with Heterozygous Familial Hypercholesterolemia (HeFH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeterozygous Familial Hypercholesterolemia
CountriesDenmark, Netherlands, Norway
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 31, 2017
Enrollment StartFeb 23, 2017
Primary CompletionJan 15, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.4 years ago

Arms & Interventions

MGL-3196experimental

Study Drug

Drug: MGL-3196 (resmetirom)
Placeboplacebo_comparator

Matching Placebo

Drug: Placebo

Interventions

MGL-3196 (resmetirom)drug

Oral

Placebodrug

Oral